Lonza, a Swiss-based ingredient supplier of peptides, amino acids and bioproducts tofor the personal care, nutrition, hygiene, preservation and agro industries, announced it has signed an exclusive agreement with CELLution Biotech BV, a technology and tool designer of single-use bioreactor systems.
The agreement gives Lonza the global rights to market and sell the CELL-tainer—a new, single-use bioreactor with non-invasive sensors—that will give the biopharmaceutical industry higher product yields. CELL-tainer shortens the development time for processing mammalian and microbial-produced biopharmaceuticals, offering clients higher cell densities and higher productivity within cell cultures.
The agreement gives Lonza the global rights to market and sell the CELL-tainer—a new, single-use bioreactor with non-invasive sensors—that will give the biopharmaceutical industry higher product yields. CELL-tainer shortens the development time for processing mammalian and microbial-produced biopharmaceuticals, offering clients higher cell densities and higher productivity within cell cultures.
